C
CapsoVision, Inc
CVCIK 0001378325NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
$13.55M
Net Income
$-25.32M
Total Assets
$18.16M
Equity
$13.26M
Shares Out
49.84M
Op. Cash Flow
$-22.86M
Business
CapsoVision, Inc is a publicly listed company in Electromedical & Electrotherapeutic Apparatus, incorporated in Delaware. Common stock trades on Nasdaq under the ticker CV.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Net revenue | 14 | 12 | |
| Costs of revenue | 6 | 5 | |
| Gross profit | 7 | 6 | |
| Selling and marketing | 8 | 7 | |
| Research and development | 18 | 15 | |
| General and administrative | 7 | 4 | |
| Total operating expenses | 33 | 26 | |
| Operating loss | −26 | −20 | |
| Interest income, net | 269,000 | 26,000 | |
| Other non-operating income (expense), net | −44,000 | 4,000 | |
| Total non-operating income, net | 225,000 | 30,000 | |
| Loss before income taxes | −25 | −20 | |
| Provision for income taxes | 24,000 | 11,000 | |
| Net loss | −25 | −20 | |
| Net loss per share - basic (in dollars per share) | −1.03 | −9.85 | |
| Net loss per share - diluted (in dollars per share) | −1.03 | −9.85 | |
| Weighted-average common shares outstanding - basic (in shares) | 25 | 2 | |
| Weighted-average common shares outstanding - diluted (in shares) | 25 | 2 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 10 | 9 | — | |
| Accounts receivable, net | 2 | 2 | — | |
| Inventory | 3 | 3 | — | |
| Prepaid expenses and other current assets | 1 | 898,000 | — | |
| Total current assets | 17 | 15 | — | |
| Property and equipment, net | 611,000 | 720,000 | — | |
| Operating lease right-of-use assets | 843,000 | 1 | — | |
| Other long-term assets | 41,000 | 41,000 | — | |
| TOTAL ASSETS | 18 | 17 | — | |
| Accounts payable | 1 | 749,000 | — | |
| Accrued expenses and other current liabilities | 3 | 569,000 | — | |
| Deferred revenue | 177,000 | 132,000 | 96,000 | |
| Operating lease liabilities - current | 410,000 | 351,000 | — | |
| Total current liabilities | 4 | 2 | — | |
| Operating lease liabilities long-term | 477,000 | 887,000 | — | |
| Total liabilities | 5 | 3 | — | |
| Commitments and contingencies - Note 9 | — | — | — | |
| Total convertible preferred stock | 0 | 144 | 129 | |
| Common stock, $0.001 par value: 300,000,000 and 190,000,000 shares authorized; 46,865,051 and 2,090,945 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 47,000 | 2,000 | — | |
| Additional paid-in capital | 169 | 838,000 | — | |
| Accumulated deficit | −156 | −130 | — | |
| Total stockholders equity (deficit) | 13 | −130 | −110 | |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS EQUITY (DEFICIT) | 18 | 17 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Depreciation and amortization | 216,000 | 206,000 | |
| Loss on disposal of property and equipment | 1,000 | 0 | |
| Amortization of operating lease right-of-use assets | 351,000 | 315,000 | |
| Unrealized foreign exchange (gains) losses | −173,000 | 103,000 | |
| Stock in lieu of debt repayment | 31,000 | 0 | |
| Stock-based compensation | 826,000 | 156,000 | |
| Bad debt expense | 11,000 | 8,000 | |
| Accounts receivable | −478,000 | −176,000 | |
| Inventory | −358,000 | −434,000 | |
| Prepaid expenses and other current assets | −174,000 | −316,000 | |
| Other long-term assets | 0 | 1,000 | |
| Accounts payable | 376,000 | 388,000 | |
| Accrued expenses and other current liabilities | 2 | −204,000 | |
| Deferred revenue | 45,000 | 36,000 | |
| Operating lease liabilities | −351,000 | −276,000 | |
| Net cash used in operating activities | −23 | −20 | |
| Purchases of property and equipment | −90,000 | −153,000 | |
| Net cash used in investing activities | −90,000 | −153,000 | |
| Proceeds from issuance of Series H convertible preferred stock | 0 | 15 | |
| Proceeds from IPO, net of commissions | 27 | 0 | |
| Payment of IPO offering costs | −3 | 0 | |
| Proceeds from promissory note issuance | 1 | 0 | |
| Repayment of promissory note | −1 | 0 | |
| Proceeds from exercises of options on common stock and warrants | 231,000 | 74,000 | |
| Net cash provided by financing activities | 24 | 15 | |
| Net increase (decrease) in cash and cash equivalents | 650,000 | −5 | |
| Effect of exchange rate changes on cash and cash equivalents | 143,000 | −70,000 | |
| Cash paid for income taxes | 9,000 | 6,000 | |
| Cash paid for interest | 15,000 | 0 | |
| Underwriters warrants issued in connection with the IPO | 519,000 | 0 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro